|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heidenreich A, Bastian PJ, Bellmunt J,
Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T,
Zattoni F, et al: EAU guidelines on prostate cancer. part 1.
Screening, diagnosis, and local treatment with curative
intent-update 2013. Eur Urol. 65:124–137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heidenreich A, Bastian PJ, Bellmunt J,
Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T,
Zattoni F, et al: EAU guidelines on prostate cancer. Part II:
Treatment of advanced, relapsing and castration-resistant prostate
cancer. Eur Urol. 65:467–479. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saad F and Hotte SJ: Guidelines for the
management of castrate-resistant prostate cancer. Can Urol Assoc J.
4:380–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sporn MB and Suh N: Chemoprevention of
cancer. Carcinogenesis. 21:525–530. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
William WN Jr, Heymach JV, Kim ES and
Lippman SM: Molecular targets for cancer chemoprevention. Nat Rev
Drug Discov. 8:213–225. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Violette PD and Saad F: Chemoprevention of
prostate cancer: Myths and realities. J Am Board Fam Med.
25:111–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Burhans WC and Heintz NH: The cell cycle
is a redox cycle: Linking phase-specific target to cell fate. Free
Radic Biol Med. 47:1282–1293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pietenpol JA and Stewart ZA: Cell cycle
checkpoint signaling: Cell cycle arrest versus apoptosis.
Toxicology. 181–182:475–481. 2002. View Article : Google Scholar
|
|
10
|
Circu ML and Aw TY: Reactive oxygen
species, cellular redox systems, and apoptosis. Free Radic Biol
Med. 48:749–762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pompella A, Visvikis A, Paolicchi A, De
Tata V and Casini AF: The changing faces of glutathione, a cellular
protagonist. Biochem Pharmacol. 66:1499–1503. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li MH, Chen JM, Peng Y, Wu Q and Xiao PG:
Investigation of Danshen and related medicinal plants in China. J
Ethnopharmacol. 120:419–426. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gong Y, Li Y, Lu Y, Li L, Abdolmaleky H,
Blackburn GL and Zhou JR: Bioactive tanshinones in Salvia
miltiorrhiza inhibit the growth of prostate cancer cells in
vitro and in mice. Int J Cancer. 129:1042–1052. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Y, Won SH, Jiang C, Lee HJ, Jeong
SJ, Lee EO, Zhang J, Ye M, Kim SH and Lü J: Tanshinones from
Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge)
suppress prostate cancer growth and androgen receptor signaling.
Pharm Res. 29:1595–1608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu WY and Wang YP: Pharmacological actions
and therapeutic applications of Salvia miltiorrhiza depside
salt and its active components. Acta Pharmacol Sin. 33:1119–1130.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
National Institutes of Health. https://clinicaltrials.gov/ct2/results?term=NCT00797953&Search=Search
|
|
18
|
Su CY, Ming QL, Rahman K, Han T and Qin
LP: Salvia miltiorrhiza: Traditional medicinal uses,
chemistry, and pharmacology. Chin J Nat Med. 13:163–182.
2015.PubMed/NCBI
|
